PE Firm Actis Sinks $48M Into India's Symbiotec Pharmalab

Law360, New York (October 22, 2013, 6:09 PM EDT) -- Private equity house Actis LLP will invest $48 million into India-based pharmaceutical company Symbiotec Pharmalab Ltd., the firm said Tuesday.

London-based Actis is hoping to build on Symbiotec’s current success as the second largest Asian producer of steroid-hormone active pharmaceutical ingredients, or APIs, which are used to manufacture medications for inflammation, asthma, immune functions and infertility.

Symbiotec, which entered the pharmaceutical market in 1995, holds the largest number of active pharmaceutical ingredient manufacturing plants approved by the U.S. Food and Drug Administration in the world, according...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.